Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients

Figures & data

Table I. Patient characteristics.

Variable	Mean	SD
Age (year)	60.41	6.75
Serum PSA level (ng/ml)	2.32	2.68
Serum FBG level (mg/dl)	102.19	48.49
Serum total cholesterol level (mg/dl)	193.40	38.37
Serum HDL-cholesterol level (mg/dl)	40.07	10.76
Serum triglyceride level (mg/dl)	154.38	108.16
Prostate volume (ml)	38.71	25.60
Post-void urine volume (ml)	98.69	107.93
Qmax (ml/sn)	14.37	7.79
IIEF	18.58	6.64
IPSS	10.76	5.31

SD, standard deviation; PSA, prostate specific antigen; FBG, fasting blood glucose; HDL, high density lipoprotein; Q_max, maximum urine flow rate; IIEF, international index of erectile function; IPSS, international prostate symptom score.

Table II. Association between ED and LUTS severities.

LUTS severity	Mild/No ED (IIEF 17–30)	Moderate/Severe ED (IIEF 6–16)	Total	p Value
Mild (IPSS 0–7)	78.8% (n = 26)	21.2% (n = 7)	100% (n = 33)	0.303
Moderate (IPSS 8–19)	65.1% (n = 43)	34.9% (n = 23)	100% (n = 66)
Severe (IPSS 20–35)	57.1% (n = 4)	42.9% (n = 3)	100% (n = 7)

LUTS, lower urinary tract symptoms; ED, erectile dysfunction; IPSS, international prostate symptom score; IIEF, international index of erectile function.

Table III. Association between MetS presence and ED–LUTS severities.

	MetS (+)	MetS (−)	Total	p Value
ED severity
Mild/No ED (IIEF 17–30)	24.7% (n = 18)	75.3% (n = 55)	100% (n = 73)	0.032
Moderate/Severe ED (IIEF 6–16)	45.4% (n = 15)	54.6% (n = 18)	100% (n = 33)
LUTS severity
Mild (IPSS 0–7)	42.4% (n = 14)	57.6% (n = 19)	100% (n = 33)	0.144
Moderate (IPSS 8–19)	24.2% (n = 16)	75.8% (n = 50)	100% (n = 66)
Severe (IPSS 20–35)	42.9% (n = 3)	57.1% (n = 4)	100% (n = 7)

MetS, metabolic syndrome; ED, erectile dysfunction; LUTS, lower urinary tract symptoms; IPSS, international prostate symptom score; IIEF, international index of erectile function.